Get the Stockscreener App
0.1801
2.60%
-0.0048
After Hours:
.18
-0.0001
-0.06%
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Forecast
The Adaptimmune Therapeutics Plc Adr (ADAP) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $6.7206, representing a +3,632% increase from the current price of $0.1801. The highest analyst price target is $8.4969, and the lowest is $4.9442.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month ADAP Price Target
Average 4.8958
(+2,618% Upside)
Is Adaptimmune Therapeutics Plc Adr (ADAP) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 59.48 | Neutral |
| STOCH(9,6) | 50.77 | Neutral |
| STOCHRSI(14) | 35.48 | Neutral |
| MACD(12,26) | 0.024 | Buy |
| ADX(14) | 46.62 | Buy |
| William %R | -60.06 | Neutral |
| CCI(14) | 78.14 | Neutral |
Buy: 2
Sell: 0
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.1601
Buy
|
0.1678
Buy
|
| MA20 |
0.1468
Buy
|
0.1464
Buy
|
| MA50 |
0.0971
Buy
|
0.1359
Buy
|
| MA100 |
0.1744
Buy
|
0.1821
Sell
|
| MA200 |
0.3035
Sell
|
0.3347
Sell
|
Buy: 7
Sell: 3
Neutral: 0
Summary: Buy
According to our latest analysis, ADAP could be considered a Strong Buy, with 17 technical analysis indicators signaling 9 Buy signals, 3 signaling Sell signals and 5 Neutral signals. This might be a good time to open fresh positions on ADAP, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 59.48 indicates that ADAP is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 50.77 indicates that ADAP is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 35.48 indicates that ADAP is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 46.62 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 78.14 indicates that ADAP is still overbought but not to an extreme extent.
Long-term ADAP price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Adaptimmune Therapeutics Plc Adr financial reports and earnings history, Adaptimmune Therapeutics Plc Adr (ADAP) stock could reach $2.2862 by 2030, $2.8833 by 2040 and $6.8654 by 2050. See the projected annual prices until 2050 of the Adaptimmune Therapeutics Plc Adr stock below:
- Adaptimmune Therapeutics Plc Adr (ADAP) is expected to reach an average price of $1.6701 in 2035, with a high prediction of $1.6351 and a low estimate of $1.6589. This indicates an $827.29% rise from the last recorded price of $0.1801.
- Adaptimmune Therapeutics Plc Adr (ADAP) stock is projected to chart a bullish course in 2040, with an average price target of $2.5274, representing an $1,303% surge from its current level. The forecast ranges from a conservative $2.6574 to a sky-high $2.8833.
- Our analysts predict Adaptimmune Therapeutics Plc Adr (ADAP) to jump 2,691% by 2045, soaring from $4.8148 to an average price of $5.0272, potentially reaching $5.0164. While $4.8148 is the low estimate, the potential upside is significant.
- Adaptimmune Therapeutics Plc Adr (ADAP) stock is expected to climb by 2050, reaching an average of $6.8089, a $3,681% jump from its current level. However, a wide range of estimates exists, with high and low targets of $6.8654 and $6.5234, respectively, highlighting the market's uncertainty.
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Year by Year Forecast
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Price Forecast for 2025
Adaptimmune Therapeutics Plc Adr Stock (ADAP) is expected to reach an average price of $5.4324 in 2025, with a high prediction of $10.84 and a low estimate of $0.023. This indicates an +2,916% rise from the last recorded price of $0.1801.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| November, 2025 | $5.5615 | $4.9442 | $8.4969 | +2,988% |
| December, 2025 | $2.128 | $1.768 | $6.9134 | +1,082% |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Price Forecast for 2026
The predicted value for Adaptimmune Therapeutics Plc Adr (ADAP) in 2026 is set at an average of $3.1848. Estimates vary from a peak of $5.0749 to a trough of $1.2947, indicating an +1,668% surge from the present price of $0.1801.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $2.5572 | $1.8972 | $3.3853 | +1,320% |
| February, 2026 | $2.5549 | $1.4591 | $2.7668 | +1,319% |
| March, 2026 | $3.4256 | $2.2837 | $4.1206 | +1,802% |
| April, 2026 | $4.0322 | $2.7803 | $5.0749 | +2,139% |
| May, 2026 | $2.9414 | $2.2768 | $4.2095 | +1,533% |
| June, 2026 | $2.8506 | $2.5287 | $3.8287 | +1,483% |
| July, 2026 | $2.6571 | $2.2871 | $3.7925 | +1,375% |
| August, 2026 | $2.3263 | $2.3063 | $3.4244 | +1,192% |
| September, 2026 | $2.0028 | $1.5509 | $2.4025 | +1,012% |
| October, 2026 | $1.402 | $1.2947 | $2.0801 | +678.47% |
| November, 2026 | $3.1312 | $1.3893 | $3.3812 | +1,639% |
| December, 2026 | $3.1677 | $2.8685 | $4.8358 | +1,659% |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Adaptimmune Therapeutics Plc Adr (ADAP) is $2.0019, with a high forecast of $3.9989 and a low forecast of $0.00492. This indicates an +1,012% increase from the last price of $0.1801.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $3.237 | $3.0524 | $3.6897 | +1,697% |
| February, 2027 | $2.3062 | $2.1362 | $3.9989 | +1,180% |
| March, 2027 | $1.9927 | $1.4727 | $2.4035 | +1,006% |
| April, 2027 | $1.4219 | $1.2819 | $2.265 | +689.50% |
| May, 2027 | $0.9611 | $0.7265 | $1.3992 | +433.65% |
| June, 2027 | $0.2376 | $0.2076 | $1.4734 | +31.93% |
| July, 2027 | $0.2768 | $0.00492 | $0.4695 | +53.71% |
| August, 2027 | $0.136 | $0.00873 | $0.5714 | -24.47% |
| September, 2027 | $0.1975 | $0.0944 | $0.2379 | +9.63% |
| October, 2027 | $0.0918 | $0.2482 | $0.2218 | -49.05% |
| November, 2027 | $0.211 | $0.0563 | $0.2552 | +17.14% |
| December, 2027 | $0.7575 | $0.0117 | $0.9175 | +320.59% |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Price Forecast for 2028
In 2028, Adaptimmune Therapeutics Plc Adr (ADAP) is projected to reach an average price of $0.5841, with a high projection of $1.1443 and a low estimate of $0.0239. This indicates an +224.33% rise from the last price of $0.1801.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $0.4267 | $0.3067 | $0.9148 | +136.92% |
| February, 2028 | $0.4891 | $0.0787 | $0.534 | +171.57% |
| March, 2028 | $0.1076 | $0.1476 | $0.3595 | -40.26% |
| April, 2028 | $0.7016 | $0.057 | $1.1443 | +289.57% |
| May, 2028 | $0.1019 | $0.1435 | $0.8889 | -43.44% |
| June, 2028 | $0.2773 | $0.1327 | $0.9027 | +54.00% |
| July, 2028 | $0.2466 | $0.2066 | $0.5446 | +36.90% |
| August, 2028 | $0.2469 | $0.1139 | $0.4684 | +37.11% |
| September, 2028 | $0.2577 | $0.2996 | $0.2078 | +43.10% |
| October, 2028 | $0.0915 | $0.0258 | $0.1919 | -49.20% |
| November, 2028 | $0.192 | $0.0239 | $0.1693 | +6.61% |
| December, 2028 | $0.3178 | $0.2914 | $0.2728 | +76.45% |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Price Forecast for 2029
The 2029 price forecast for Adaptimmune Therapeutics Plc Adr Stock (ADAP) is $0.567 on average, with a high prediction of $1.1139 and a low estimate of $0.0202. This represents an +214.85% increase from the previous price of $0.1801.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $0.2642 | $0.3012 | $0.2666 | +46.68% |
| February, 2029 | $0.3971 | $0.319 | $0.3486 | +120.47% |
| March, 2029 | $0.3366 | $0.3874 | $0.3603 | +86.87% |
| April, 2029 | $0.4626 | $0.4163 | $0.3996 | +156.88% |
| May, 2029 | $0.612 | $0.5613 | $0.5067 | +239.83% |
| June, 2029 | $0.5107 | $0.5829 | $0.5675 | +183.58% |
| July, 2029 | $0.2307 | $0.5232 | $0.5286 | +28.10% |
| August, 2029 | $0.0272 | $0.2389 | $0.1944 | -84.90% |
| September, 2029 | $0.522 | $0.0589 | $0.68 | +189.84% |
| October, 2029 | $0.5185 | $0.3185 | $1.1139 | +187.91% |
| November, 2029 | $0.0844 | $0.0202 | $0.7358 | -53.12% |
| December, 2029 | $1.80 | $0.055 | $0.92 | +899.44% |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Price Forecast for 2030
Adaptimmune Therapeutics Plc Adr Stock (ADAP) is expected to reach an average price of $3.1115 in 2030, with a high forecast of $4.6857 and a low forecast of $1.5374. This signifies an +1,628% surge from the last price of $0.1801.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $2.367 | $2.3854 | $2.2862 | +1,214% |
| February, 2030 | $2.4286 | $2.3032 | $2.1424 | +1,248% |
| March, 2030 | $3.3101 | $2.6339 | $2.4426 | +1,738% |
| April, 2030 | $4.1717 | $3.9655 | $4.0917 | +2,216% |
| May, 2030 | $4.1687 | $4.0479 | $4.1287 | +2,215% |
| June, 2030 | $4.7436 | $4.4841 | $4.6303 | +2,534% |
| July, 2030 | $4.7378 | $4.7324 | $4.6857 | +2,531% |
| August, 2030 | $4.1888 | $4.3288 | $4.4126 | +2,226% |
| September, 2030 | $4.1104 | $4.2042 | $4.195 | +2,182% |
| October, 2030 | $1.3574 | $1.5374 | $1.0974 | +653.68% |
| November, 2030 | $2.644 | $1.7028 | $1.9991 | +1,368% |
| December, 2030 | $2.6604 | $2.7241 | $2.3944 | +1,377% |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):